Evolutionary trends in the pharmacotherapeutic management of depression

C. B. Nemeroff, D. L. Dunner, R. M A Hirschfeld, C. L. DeVane, C. B. Montano

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

The past decade has brought an exponential increase in our knowledge of the pharmacotherapeutic management of depression. Much has been learned about the prevalence, risks, and course of depression in the general population, the elderly, and patients with comorbid medical illnesses and about the biological basis of depression. This article reviews evolving trends in the diagnosis and management of depression and evaluates the main classes of antidepressants. Although depression carries a high risk of morbidity and mortality, it is very treatable, and early diagnosis and early treatment are now emphasized. Antidepressant medication is continued after the patients' acute depressive symptoms resolve, sometimes for as long as 1 to 5 years to prevent relapse and recurrence of depression; in addition, full doses, rather than lower doses of antidepressant are prescribed for maintenance therapy. The armamentarium of antidepressants too has changed. In addition to monoamine oxidase inhibitors and tricyclic and tetracyclic antidepressants, the serotonin reuptake inhibitors fluoxetine, sertraline, and paroxetine are now available, as well as a group of antidepressants with atypical mechanisms of action that includes bupropion, trazodone, venlafaxine, and nefazodone. Although comparable in efficacy to the tricyclic antidepressants, these new drugs are safer and better tolerated because they are believed to act selectively on specific neurotransmitter systems.

Original languageEnglish (US)
Pages (from-to)3-15
Number of pages13
JournalJournal of Clinical Psychiatry
Volume55
Issue number12 SUPPL.
StatePublished - 1994

Fingerprint

Depression
Antidepressive Agents
Tricyclic Antidepressive Agents
Second-Generation Antidepressive Agents
Trazodone
Knowledge Management
Bupropion
Sertraline
Recurrence
Paroxetine
Monoamine Oxidase Inhibitors
Fluoxetine
Serotonin Uptake Inhibitors
Neurotransmitter Agents
Early Diagnosis
Morbidity
Mortality
Therapeutics
Population

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Nemeroff, C. B., Dunner, D. L., Hirschfeld, R. M. A., DeVane, C. L., & Montano, C. B. (1994). Evolutionary trends in the pharmacotherapeutic management of depression. Journal of Clinical Psychiatry, 55(12 SUPPL.), 3-15.

Evolutionary trends in the pharmacotherapeutic management of depression. / Nemeroff, C. B.; Dunner, D. L.; Hirschfeld, R. M A; DeVane, C. L.; Montano, C. B.

In: Journal of Clinical Psychiatry, Vol. 55, No. 12 SUPPL., 1994, p. 3-15.

Research output: Contribution to journalArticle

Nemeroff, CB, Dunner, DL, Hirschfeld, RMA, DeVane, CL & Montano, CB 1994, 'Evolutionary trends in the pharmacotherapeutic management of depression', Journal of Clinical Psychiatry, vol. 55, no. 12 SUPPL., pp. 3-15.
Nemeroff CB, Dunner DL, Hirschfeld RMA, DeVane CL, Montano CB. Evolutionary trends in the pharmacotherapeutic management of depression. Journal of Clinical Psychiatry. 1994;55(12 SUPPL.):3-15.
Nemeroff, C. B. ; Dunner, D. L. ; Hirschfeld, R. M A ; DeVane, C. L. ; Montano, C. B. / Evolutionary trends in the pharmacotherapeutic management of depression. In: Journal of Clinical Psychiatry. 1994 ; Vol. 55, No. 12 SUPPL. pp. 3-15.
@article{9143ed4cac3747b6b045f56d3efd70b6,
title = "Evolutionary trends in the pharmacotherapeutic management of depression",
abstract = "The past decade has brought an exponential increase in our knowledge of the pharmacotherapeutic management of depression. Much has been learned about the prevalence, risks, and course of depression in the general population, the elderly, and patients with comorbid medical illnesses and about the biological basis of depression. This article reviews evolving trends in the diagnosis and management of depression and evaluates the main classes of antidepressants. Although depression carries a high risk of morbidity and mortality, it is very treatable, and early diagnosis and early treatment are now emphasized. Antidepressant medication is continued after the patients' acute depressive symptoms resolve, sometimes for as long as 1 to 5 years to prevent relapse and recurrence of depression; in addition, full doses, rather than lower doses of antidepressant are prescribed for maintenance therapy. The armamentarium of antidepressants too has changed. In addition to monoamine oxidase inhibitors and tricyclic and tetracyclic antidepressants, the serotonin reuptake inhibitors fluoxetine, sertraline, and paroxetine are now available, as well as a group of antidepressants with atypical mechanisms of action that includes bupropion, trazodone, venlafaxine, and nefazodone. Although comparable in efficacy to the tricyclic antidepressants, these new drugs are safer and better tolerated because they are believed to act selectively on specific neurotransmitter systems.",
author = "Nemeroff, {C. B.} and Dunner, {D. L.} and Hirschfeld, {R. M A} and DeVane, {C. L.} and Montano, {C. B.}",
year = "1994",
language = "English (US)",
volume = "55",
pages = "3--15",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "12 SUPPL.",

}

TY - JOUR

T1 - Evolutionary trends in the pharmacotherapeutic management of depression

AU - Nemeroff, C. B.

AU - Dunner, D. L.

AU - Hirschfeld, R. M A

AU - DeVane, C. L.

AU - Montano, C. B.

PY - 1994

Y1 - 1994

N2 - The past decade has brought an exponential increase in our knowledge of the pharmacotherapeutic management of depression. Much has been learned about the prevalence, risks, and course of depression in the general population, the elderly, and patients with comorbid medical illnesses and about the biological basis of depression. This article reviews evolving trends in the diagnosis and management of depression and evaluates the main classes of antidepressants. Although depression carries a high risk of morbidity and mortality, it is very treatable, and early diagnosis and early treatment are now emphasized. Antidepressant medication is continued after the patients' acute depressive symptoms resolve, sometimes for as long as 1 to 5 years to prevent relapse and recurrence of depression; in addition, full doses, rather than lower doses of antidepressant are prescribed for maintenance therapy. The armamentarium of antidepressants too has changed. In addition to monoamine oxidase inhibitors and tricyclic and tetracyclic antidepressants, the serotonin reuptake inhibitors fluoxetine, sertraline, and paroxetine are now available, as well as a group of antidepressants with atypical mechanisms of action that includes bupropion, trazodone, venlafaxine, and nefazodone. Although comparable in efficacy to the tricyclic antidepressants, these new drugs are safer and better tolerated because they are believed to act selectively on specific neurotransmitter systems.

AB - The past decade has brought an exponential increase in our knowledge of the pharmacotherapeutic management of depression. Much has been learned about the prevalence, risks, and course of depression in the general population, the elderly, and patients with comorbid medical illnesses and about the biological basis of depression. This article reviews evolving trends in the diagnosis and management of depression and evaluates the main classes of antidepressants. Although depression carries a high risk of morbidity and mortality, it is very treatable, and early diagnosis and early treatment are now emphasized. Antidepressant medication is continued after the patients' acute depressive symptoms resolve, sometimes for as long as 1 to 5 years to prevent relapse and recurrence of depression; in addition, full doses, rather than lower doses of antidepressant are prescribed for maintenance therapy. The armamentarium of antidepressants too has changed. In addition to monoamine oxidase inhibitors and tricyclic and tetracyclic antidepressants, the serotonin reuptake inhibitors fluoxetine, sertraline, and paroxetine are now available, as well as a group of antidepressants with atypical mechanisms of action that includes bupropion, trazodone, venlafaxine, and nefazodone. Although comparable in efficacy to the tricyclic antidepressants, these new drugs are safer and better tolerated because they are believed to act selectively on specific neurotransmitter systems.

UR - http://www.scopus.com/inward/record.url?scp=0028607972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028607972&partnerID=8YFLogxK

M3 - Article

VL - 55

SP - 3

EP - 15

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 12 SUPPL.

ER -